An email I received today…I hope they survive to get the 180 day sensor approved in the US.
*Senseonics has been concerned since the COVID-19 outbreak, about not only the health and safety of our employees, patients, and physician partners, but about the effect that this pandemic has on our ability to deliver the Eversense CGM system to our users. Because our sensor requires an in-clinic procedure, we have seen a notable reduction in access to clinics and sensor orders/insertions overall in the past few weeks. In fact, the pandemic’s impact on the global health system and financial markets has caused Senseonics to meaningfully alter our current business plan. *
*
Regretfully, the current environment will require us to reduce our workforce, including the majority of our US sales and clinical organization, as well as halt the Bridge Program’s prior authorization and appeal services. As you can imagine, this was not an easy decision, but one we had to make to continue appropriately serving our existing customers while continuing to develop our next generation product.